R&D pipeline
Precision designed novel molecules
Cannabinoid drugs face significant challenges: safety concerns, weak intellectual property, and poor receptor selectivity. Sonas addresses all three through advanced molecular engineering resulting in entirely novel endocannabinoid structures. We optimize receptor selectivity and safety while creating novel chemical entities with enhanced efficacy over the parent molecule protected by strong, defensible patents.
Pre-clinical Optimization
Our science is delivering high-impact results. We have generated strong preclinical data for our lead candidates targeting epilepsy and obesity, demonstrating superior efficacy and an improved safety profile in validated models. These findings confirm the potential of our discovery platform and provide a confident foundation for our clinical pipeline.
Compelling Preclinical Validation
Superior Efficacy
Our lead candidate demonstrates twice the anticonvulsant activity of CBD (Epidiolex) in validated preclinical seizure models, establishing best-in-class potential.
De-risked Portfolio
Multiple backup candidates with differentiated receptor profiles provide strategic flexibility and reduce development risk.
Enhanced Safety Profile
Advanced in silico modeling predicts reduced hepatotoxicity risk and improved drug-drug interaction profile compared to current CBD therapies.
Development Plan
2026 - 2027
Complete IND enabling studies for lead candidate
2027 - 2028
Phase 1 safety and pharmacokinetic studies
2028 - 2030
Phase 2a proof-of-concept study in obesity or treatment-resistant epilepsy
2030 onwards
We are targeting a 3‑to‑5‑year exit via trade sale or IPO, aligned with Phase 1 or Phase 2 clinical validation.
Strong M&A activity in both epilepsy and obesity and strong IP, differentiated assets, and an experienced team, Sonas is well positioned for strategic interest.